Evox Therapeutics, an innovative biotechnology company spun out from Oxford University, has successfully raised £35.5 million in a Series B financing round. The round was led by Redmile Group, with notable new investments from Google’s GV, Cowen Healthcare Investments, and several others. This funding follows a previous £10 million raised from Oxford Sciences Innovation during a Series A seed financing round.

The fresh capital injection will support Evox Therapeutics as it advances its pipeline of exosome-based therapeutics. The funds are earmarked for pushing various rare disease assets towards clinical stages and for the ongoing development of its revolutionary exosome drug platform. Evox stands out in the biotech industry for its focus on harnessing exosomes — natural vesicular delivery systems in the body — to enable drug delivery to previously inaccessible tissue and organ compartments.

Evox Therapeutics is pioneering modifications to exosomes to enhance the delivery capabilities of a broad spectrum of drugs. This includes crossing the blood-brain barrier to deliver drugs to the central nervous system, extra-hepatic delivery of RNA therapeutics, and intracellular delivery of biologics. Dr. Antonin de Fougerolles, CEO of Evox Therapeutics, expressed optimism about the transformative potential of their exosome technology, which aims to improve and enable the delivery of therapeutic molecules such as antibodies, proteins, nucleic acids, and small molecules.

The additional funding is expected to significantly advance Evox’s pipeline of innovative exosome-based therapeutics towards clinical trials. The company is also actively seeking partnerships with major pharmaceutical companies to expand the application of its exosome technology for the treatment of a variety of other diseases. With a robust intellectual property portfolio and expanded internal R&D capabilities, Evox Therapeutics is poised for substantial growth in the biotechnology sector.

Evox Therapeutics’ recent funding achievement marks a pivotal milestone in its quest to develop groundbreaking treatments for rare, life-threatening diseases. With a strong focus on exosome technology, the company is leading the way in exploring new frontiers in drug delivery and therapeutic efficacy.

  biotech innovation, biotechnology, Cowen Healthcare Investments, Dr Antonin de Fougerolles, Evox Therapeutics, Evox Therapeutics funding, exosome technology, exosome-based therapeutics, Google, GV, Jeremy Green, Oxford biotech, Oxford Sciences Innovation, Oxford University, rare disease research, rare disease treatment, Redmile Group, Series B Funding, United Kingdom